520 related articles for article (PubMed ID: 25795391)
1. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece.
Athanasakis K; Boubouchairopoulou N; Tarantilis F; Tsiantou V; Kontodimas S; Kyriopoulos J
Clin Ther; 2017 May; 39(5):993-1002. PubMed ID: 28449867
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain.
Elías I; Ortega-Joaquín N; de la Cueva P; Del Pozo LJ; Moreno-Ramírez D; Boada A; Aguilar M; Mirada A; Mosquera E; Gibbons C; Oyagüez I
Actas Dermosifiliogr; 2016; 107(6):498-508. PubMed ID: 27130804
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility of first-line actinic keratosis treatments in Finland.
Soini EJ; Hallinen T; Sokka AL; Saarinen K
Adv Ther; 2015 May; 32(5):455-76. PubMed ID: 26006101
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of 5-fluorouracil 0.5%/salicylic acid 10% in the treatment of actinic keratosis in Spain.
Nieves D; Puig-Peiró R; Ferrándiz C; Plazas MJ; Brosa M
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):539-43. PubMed ID: 25495775
[TBL] [Abstract][Full Text] [Related]
6. Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis.
Nisticò S; Del Duca E; Torchia V; Gliozzi M; Bottoni U; Muscoli C
Int J Immunopathol Pharmacol; 2018; 32():2058738418757925. PubMed ID: 29442526
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of 5-FU-SA in the treatment of actinic keratoses of the face and scalp in the UK secondary care setting.
Wojcik R; Lowin J; Vilardell D; Maeso S; Ruiz L; Lear JT; Morton C
J Med Econ; 2017 Mar; 20(3):221-227. PubMed ID: 27715356
[TBL] [Abstract][Full Text] [Related]
8. Ingenol mebutate gel for actinic keratosis.
Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses.
Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK
JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119
[TBL] [Abstract][Full Text] [Related]
10. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
Keating GM
Drugs; 2012 Dec; 72(18):2397-405. PubMed ID: 23231025
[TBL] [Abstract][Full Text] [Related]
11. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes.
Augustin M; Tu JH; Knudsen KM; Erntoft S; Larsson T; Hanke CW
J Am Acad Dermatol; 2015 May; 72(5):816-21. PubMed ID: 25770879
[TBL] [Abstract][Full Text] [Related]
12. A multicentre, open, investigator-initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0·015% on the face and scalp, and 0·05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT).
Kim YC; Yang JY; Yoon JS; Jo SJ; Ahn HH; Song KH; Lee DY; Chung KY; Won YH; Kim IH
Br J Dermatol; 2018 Oct; 179(4):836-843. PubMed ID: 29355904
[TBL] [Abstract][Full Text] [Related]
13. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).
Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F
Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques.
Ruini C; Hartmann D; Bastian M; Ruzicka T; French LE; Berking C; von Braunmühl T
J Biophotonics; 2019 Jul; 12(7):e201800391. PubMed ID: 30653833
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
Berman B
Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
[TBL] [Abstract][Full Text] [Related]
16. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice.
Bettencourt MS
J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570
[TBL] [Abstract][Full Text] [Related]
17. A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands.
Jansen MHE; Kessels JPHM; Merks I; Nelemans PJ; Kelleners-Smeets NWJ; Mosterd K; Essers BAB
Br J Dermatol; 2020 Oct; 183(4):738-744. PubMed ID: 31961446
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results.
Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Larsson T; Swanson N
J Drugs Dermatol; 2014 Jun; 13(6):741-7. PubMed ID: 24918567
[TBL] [Abstract][Full Text] [Related]
19. Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp.
Stockfleth E; Harwood CA; Serra-Guillén C; Larsson T; Østerdal ML; Skov T
Br J Dermatol; 2018 Feb; 178(2):433-442. PubMed ID: 29030864
[TBL] [Abstract][Full Text] [Related]
20. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M
Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
